近日,苏州旺山旺水生物医药股份有限公司(下称“旺山旺水”)递交了港股招股说明书,拟募集资金用于产品研发、青岛工厂建设、营销能力强化等项目,同时补充营运资金。旺山旺水主要从事创新小分子药物的发现、开发和商业化工作,主要聚焦于病毒感染、神经精神及生殖健康领域。核心产品面临市场竞争压力旺山旺水目前拥有9条研发管线,包括两个核心产品LV232、TPN171,以及一款关键产品VV116。VV116是公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.